feed,title,long_url,short_url
Investors,Top-Notch Biotech Mesoblast Skyrockets 29% On Immune Condition Approval,https://www.investors.com/news/technology/mesoblast-biotech-stock-graft-versus-host-disease-ryoncil-approval/,https://da.gd/LxHWRJ
